EGFR-mutation testing, treatment patterns and clinical outcomes in patients with stage IB–IIIA non-small cell lung cancer in Norway–a nationwide cohort study

Åslaug Helland,Tor Åge Myklebust,Simona Conte,Line Elmerdahl Frederiksen,Jørgen Aarøe,Espen Enerly

Cancer Treatment and Research Communications（2024）

引用 0|浏览4

暂无评分

摘要

•The study included 2367 patients with localized non-small cell lung cancer.•Most patients were treated with surgery (66 %), while 16 % received radiotherapy.•EGFR-mutation testing increased significantly from 58 to 84 % during the study period.•9 % of tested patients were EGFRm+, of whom 27 % were treated with EGFR-TKIs.•EGFRm+ patients had a higher 3-year OS (78.8 %) than EGFRwt patients (65.9 %).

查看译文

关键词

Non-small cell lung cancer,Epidermal growth factor receptor,Tyrosine kinase inhibitors,Real-world evidence,Overall survival

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要